BRPI0209134B8 - uso de um sevelamer ou um sal do mesmo e uso de um colesevelam ou um sal do mesmo - Google Patents

uso de um sevelamer ou um sal do mesmo e uso de um colesevelam ou um sal do mesmo

Info

Publication number
BRPI0209134B8
BRPI0209134B8 BRPI0209134A BRPI0209134B8 BR PI0209134 B8 BRPI0209134 B8 BR PI0209134B8 BR PI0209134 A BRPI0209134 A BR PI0209134A BR PI0209134 B8 BRPI0209134 B8 BR PI0209134B8
Authority
BR
Brazil
Prior art keywords
salt
polymer
colesevelam
amine
patient
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
K Burke Steven
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR0209134A publication Critical patent/BR0209134A/pt
Publication of BRPI0209134B1 publication Critical patent/BRPI0209134B1/pt
Publication of BRPI0209134B8 publication Critical patent/BRPI0209134B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0209134 2001-04-18 2002-04-10 uso de um sevelamer ou um sal do mesmo e uso de um colesevelam ou um sal do mesmo BRPI0209134B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28444501P 2001-04-18 2001-04-18
US30556401P 2001-07-13 2001-07-13
PCT/US2002/011493 WO2002085377A1 (en) 2001-04-18 2002-04-10 Method for lowering serum glucose

Publications (3)

Publication Number Publication Date
BR0209134A BR0209134A (pt) 2004-06-15
BRPI0209134B1 BRPI0209134B1 (pt) 2019-08-27
BRPI0209134B8 true BRPI0209134B8 (pt) 2021-05-25

Family

ID=26962623

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0209134 BRPI0209134B8 (pt) 2001-04-18 2002-04-10 uso de um sevelamer ou um sal do mesmo e uso de um colesevelam ou um sal do mesmo

Country Status (17)

Country Link
US (2) US7229613B2 (https=)
EP (1) EP1392331B1 (https=)
JP (2) JP4499363B2 (https=)
KR (1) KR20040018358A (https=)
CN (1) CN1511039A (https=)
AT (1) ATE390927T1 (https=)
AU (1) AU2002257145B2 (https=)
BR (1) BRPI0209134B8 (https=)
CA (1) CA2444046C (https=)
CY (1) CY1119486T1 (https=)
DE (1) DE60225908T2 (https=)
DK (2) DK1392331T3 (https=)
ES (2) ES2637020T3 (https=)
MX (1) MXPA03009568A (https=)
NZ (1) NZ528831A (https=)
PT (1) PT1923064T (https=)
WO (1) WO2002085377A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
CA2444046C (en) * 2001-04-18 2011-06-07 Steven K. Burke Use of colesevelam in reducing serum glucose
US7220406B2 (en) * 2002-10-22 2007-05-22 Genzyme Corporation Method for promoting bone formation
US7335795B2 (en) * 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
CN1953756A (zh) * 2004-03-26 2007-04-25 三菱制药株式会社 胰岛素抗性改善剂
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
WO2006072054A1 (en) * 2004-12-30 2006-07-06 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
US8986669B2 (en) * 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
EP3000460A1 (en) 2005-09-15 2016-03-30 Genzyme Corporation Sachet formulation for amine polymers
EP1945196A2 (en) * 2005-11-08 2008-07-23 Genzyme Corporation Magnesium-containing polymers for hyperphosphatemia
WO2008005217A2 (en) * 2006-07-05 2008-01-10 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
US7964182B2 (en) * 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
CA2749074A1 (en) * 2006-09-01 2008-05-29 Usv Limited Process for the preparation of sevelamer hydrochloride and formulation thereof
EP2066293A2 (en) 2006-09-29 2009-06-10 Genzyme Corporation Amide dendrimer compositions
US8163799B2 (en) 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
EP2361171A4 (en) * 2008-09-15 2014-11-05 Shasun Chemicals And Drugs Ltd PROCESS FOR PREPARING NETWORKED POLYMERS IN A NON-AQUEOUS SOLUTION
US20110081413A1 (en) * 2009-01-22 2011-04-07 Ashok Omray Pharmaceutical Compositions Comprising Phosphate-Binding Polymer
WO2014122586A1 (en) 2013-02-08 2014-08-14 Wockhardt Limited Oral pharmaceutical composition of aliphatic amine polymer or salts thereof
HK1220607A1 (zh) * 2013-03-15 2017-05-12 Genzyme Corporation 晚期糖化终产物(age)前体的螯合剂
CN106573066A (zh) 2014-06-13 2017-04-19 联合治疗学有限公司 曲前列环素制剂
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
BR112019013364A2 (pt) 2016-12-28 2020-04-14 Fujifilm Corp emulsão de polímero contendo átomo de nitrogênio ou sal do mesmo, método de produção para o mesmo e método de produção para partículas
CN111225674A (zh) 2017-10-16 2020-06-02 富士胶片株式会社 高磷血症治疗剂
EP4161534B1 (en) 2021-08-24 2024-11-06 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia
EP4164659B1 (en) 2021-08-24 2024-03-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4528847A (en) * 1983-10-04 1985-07-16 D. Halmi And Associates, Inc. Flow metering device with recessed pressure taps
JPS6090243A (ja) 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US4528347A (en) 1983-11-10 1985-07-09 501 Nitto Boseki, Co. Ltd Process for producing polymers of monoallylamine
US5468727A (en) * 1990-12-13 1995-11-21 Board Of Regents, The University Of Texas System Methods of normalizing metabolic parameters in diabetics
JP3507523B2 (ja) 1993-05-12 2004-03-15 積水化学工業株式会社 糖質吸収抑制剤
US5487888A (en) 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5624963A (en) 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5703188A (en) 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5900475A (en) 1994-06-10 1999-05-04 Geltex Pharmaceuticals, Inc. Hydrophobic sequestrant for cholesterol depletion
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
JP4156684B2 (ja) * 1996-03-05 2008-09-24 三菱化学株式会社 高リン血症予防および／または治療剤
US6203785B1 (en) 1996-12-30 2001-03-20 Geltex Pharmaceuticals, Inc. Poly(diallylamine)-based bile acid sequestrants
US5925379A (en) 1997-03-27 1999-07-20 Geltex Pharmaceuticals, Inc. Interpenetrating polymer networks for sequestration of bile acids
TW592727B (en) 1997-04-04 2004-06-21 Chugai Pharmaceutical Co Ltd Phosphate-binding polymer preparations
US6423754B1 (en) 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
FR2766195A1 (fr) 1997-07-21 1999-01-22 Transgene Sa Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charges negative, notamment des acides nucleiques, et leur utilisation en therapie genique
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
AU2682499A (en) 1998-02-17 1999-08-30 Dimitri R. Kioussis Anion binding polymers and the use thereof
EP1340510A1 (en) * 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
WO2001025291A1 (en) * 1999-10-07 2001-04-12 University Of Maryland Sugar binding polymers and the use thereof
TWI241195B (en) * 2000-04-10 2005-10-11 Shionogi & Co Preventive agent for bile acidic diarrhea
CA2444046C (en) * 2001-04-18 2011-06-07 Steven K. Burke Use of colesevelam in reducing serum glucose
US20020198202A1 (en) 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and an antilipemic agent

Also Published As

Publication number Publication date
JP4499363B2 (ja) 2010-07-07
CA2444046A1 (en) 2002-10-31
DE60225908T2 (de) 2009-05-14
CY1119486T1 (el) 2018-03-07
WO2002085377A1 (en) 2002-10-31
DK1392331T3 (da) 2008-06-23
ES2304437T3 (es) 2008-10-16
US20070286841A1 (en) 2007-12-13
PT1923064T (pt) 2017-08-23
WO2002085377A8 (en) 2002-11-28
ES2637020T3 (es) 2017-10-10
CN1511039A (zh) 2004-07-07
DK1923064T3 (en) 2017-10-02
KR20040018358A (ko) 2004-03-03
BR0209134A (pt) 2004-06-15
JP2004535384A (ja) 2004-11-25
NZ528831A (en) 2005-07-29
EP1392331B1 (en) 2008-04-02
ATE390927T1 (de) 2008-04-15
CA2444046C (en) 2011-06-07
BRPI0209134B1 (pt) 2019-08-27
US20020187121A1 (en) 2002-12-12
JP2010090172A (ja) 2010-04-22
AU2002257145B2 (en) 2005-06-02
US7229613B2 (en) 2007-06-12
DE60225908D1 (de) 2008-05-15
MXPA03009568A (es) 2004-02-12
EP1392331A1 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
BRPI0209134B8 (pt) uso de um sevelamer ou um sal do mesmo e uso de um colesevelam ou um sal do mesmo
BR0209133A (pt) Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangue
MY125874A (en) Use of polyallylamine polymers for the manufacture of a medicament for treating hypercholesterolemia
EP1645278A3 (en) Use of aliphatic polyamines for reducing oxalate
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
PT1409006E (pt) Misturas monodispersas e métodos de tratamento de diabetes
DE69713335D1 (de) Polymere zur abgabe von stickstoffoxide in vivo
ATE175864T1 (de) Stabile säure öl-in-wasser emulsionen
TR200100111T2 (tr) Kalsiyum (3S)tetrahidro-3-furanil(1S,2R)-3- [[(4-aminofenil)sulfonil)(isobutil)amino] -1-benzil-2-(fosfonooksi) propilkarbamat
NO20025627D0 (no) Fremgangsmåter og sammensetninger for å behandle hepatitt C virus
RU2008121750A (ru) Ионофоретическая доставка ротиготина для лечения болезни паркинсона
BR0211400A (pt) Tratamento de distrofia muscular com células de sangue do cordão
PT911331E (pt) Compostos de dibenzoxazepina substituidos composicoes farmaceuticas e metodos de utilizacao
BRPI0413682A (pt) compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos
BRPI0413684A (pt) compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos
BR9807408A (pt) Polìmeros de vinila reticulados tendo ação de absorvente do ácido biliar
EP1923064A3 (en) Use of amine polymer for lowering serum glucose
BR0214557A (pt) regime de dosagem de eritropoietina para o tratamento de anemia
WO2004047779A3 (en) Polymers containing quaternary ammonium salts
BRPI0507853A (pt) processo para o tratamento de material de fibra e nova composição
NO20034453D0 (no) Anvendelse av CD25-bindende molekyler i steroid-resistente pasienter
BR0307196A (pt) Idraparinux (sanorg 34006) para tratamento e profilaxia secundária de eventos tromboembólicos venosos em pacientes com trombose venosa profunda
EA200100539A1 (ru) Новый способ лечения
DE60020550D1 (de) Methode und mittel zur behandlung eines post-poliosyndroms
TH50751A (th) วิธีการลดออกซาเลต

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: GENZYME CORPORATION (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 018080029522/SP DE 14/05/2008.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/04/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 10/04/2022